Hayley Virgil

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.

Several discrepancies in care must be considered to properly address psychological needs in patients with lymphoma, including patient/doctor communication, information provision, and applying distress guidelines.

Despite seeming to elicit more pathological complete responses (pCRs) in patients with hormone receptor–positive (HR+), HER2-negative triple-negative breast cancer (BC) receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.

Hope S. Rugo, MD, FASCO, professor of medicine and director, Breast Oncology and Clinical Trials Education, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, said PALOMA-2 results don’t match what she has seen in practice.

Joel Neal, MD, PHD, associate professor, Division of Oncology, Stanford Cancer Institute, discussed phase 1b results in COSMIC-021 in non-small cell lung cancer.

Kim A. Reiss, MD, assistant program director, assistant professor of medicine, Hospital of the University of Pennsylvania, Philadelphia, discusses 2 abstracts presented during ASCO.